2024
Female Fertility Preservation for Oncological Reasons
Erden M, Oktay K. Female Fertility Preservation for Oncological Reasons. 2024 DOI: 10.1016/b978-0-443-21477-6.00277-7.Peer-Reviewed Original ResearchGonadotoxic chemotherapyPrimordial folliclesOvarian tissue cryopreservationFertility preservation techniquesFemale fertility preservationFertility preservation interventionFertility preservation optionsEnhanced DNA repairPelvic radiotherapyOvarian suppressionRadical surgeryOvarian insufficiencyTissue cryopreservationOncological reasonsOvarian damageFertility preservationPharmacological optionsPharmacological agentsPre-treatment preparationPreservation optionsCancer treatmentApoptotic deathBiological parenthoodChemotherapyDNA double-strand breaks
2020
Impact of breast cancer chemotherapy on ovarian damage and recovery.
Goldfarb S, Bedoschi G, Turan V, Crown A, Abdo N, Dickler M, Oktay K. Impact of breast cancer chemotherapy on ovarian damage and recovery. Journal Of Clinical Oncology 2020, 38: e24059-e24059. DOI: 10.1200/jco.2020.38.15_suppl.e24059.Peer-Reviewed Original ResearchAMH recoveryBreast cancerBaseline AMHOvarian reserveNon-metastatic breast cancerBaseline AMH levelsTime of diagnosisBreast cancer patientsBreast cancer chemotherapyImpact of chemoImportant predictorCancer ptsChemo groupGonadotoxic chemoChemotherapy regimenOvarian damageSerum AMHAMH levelsStudy entryTamoxifen treatmentFertility preservationLow AMHProspective studyCancer patientsFuture fertility
2015
Menstruation is an unreliable surrogate in the assessment of ovarian damage by chemotherapy: a prospective longitudinal study with AMH levels as the gold standard
Bedoschi G, Goldfarb S, Quistorff J, Goswami S, Moy F, Dickler M, Oktay K. Menstruation is an unreliable surrogate in the assessment of ovarian damage by chemotherapy: a prospective longitudinal study with AMH levels as the gold standard. Fertility And Sterility 2015, 104: e262-e263. DOI: 10.1016/j.fertnstert.2015.07.825.Peer-Reviewed Original ResearchChapter 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment
Turan V, Oktay K. Chapter 4 The Current Understanding of Clinical Data on Ovarian Toxicity from Cancer Treatment. 2015, 47-61. DOI: 10.1016/b978-0-12-801591-9.00004-7.Peer-Reviewed Original ResearchCancer treatmentComplications of chemotherapySystemic lupus erythematosusPremature ovarian insufficiencyQuality of lifeOvarian damageLupus erythematosusOvarian toxicityAutoimmune diseasesOvarian functionBRCA mutationsReproductive ageRelative riskChemotherapy agentsClinical dataOvarian insufficiencySurvival rateChemotherapeutic agentsOvarian cellsChemotherapyHuman dataTreatmentCurrent understandingErythematosusComplications
2009
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Badawy A, Elnashar A, El-Ashry M, et al (Mansura Univ, Egypt; et al) Fertil Steril 91:694-697, 2009§
Oktay K, Sönmezer M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Badawy A, Elnashar A, El-Ashry M, et al (Mansura Univ, Egypt; et al) Fertil Steril 91:694-697, 2009§. Breast Diseases A Year Book Quarterly 2009, 20: 458-460. DOI: 10.1016/s1043-321x(09)79420-2.Peer-Reviewed Original Research